Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VTAK vs ERNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VTAK Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–2 Matrix Metrics)

VTAK Overall Winner 6-Pillar Tally: VTAK 2 – 2 ERNA (2 Tie) Matrix Metrics: VTAK 4 – 2 ERNA

As of Nov 16, 2026, Catheter Precision, Inc. (VTAK) is the stronger overall head-to-head candidate over Ernexa Therapeutics Inc. (ERNA) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). VTAK carries a Unified Composite Score of 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin), whereas ERNA carries 45.6/100 (HOLD) at $1.69 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile ERNA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTAK vs ERNA
VTAK NYSE American Head-to-Head Winner
Catheter Precision, Inc.
Surgical & Medical Instruments & Apparatus
$0.15
-0.66% 1D
Market Cap $548,639
TTM Revenue $1.9M
Forward P/E N/M
Beta / 30D Vol 0.19β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 72.0 Fund 70.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -53.4%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $0.16 · SMA50: $0.21
ERNA NASDAQ
Ernexa Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$1.69
+0.6% 1D
Market Cap $2.8M
TTM Revenue $1,000
Forward P/E N/M
Beta / 30D Vol -5.48β · 90% Vol
Unified Composite Score
45.6 / 100 HOLD
Tech 36.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -27.5%), weak momentum, RSI 35
RSI-14: 34.5 · SMA20: $1.97 · SMA50: $2.70

6-Pillar Scorecard Institutional Category Breakdown (VTAK 2 – 2 ERNA)

Columns: Metric · VTAK · ERNA
1. Valuation Multiples VTAK
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.3x N/M
2. Growth & Scale VTAK
Revenue Growth (YoY) +380.7% -94.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.9M $1,000
Market Cap $548,639 $2.8M
3. Profitability & Quality ERNA
Gross Margin 47.7% 100.0%
Operating Margin -388.1% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -111.3% -320.7%
4. Balance Sheet & Cash Flow ERNA
Cash Generation (TTM) -$10M EBITDA -$12M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.87 Book/Sh · -111.3% ROE $8.8M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTAK (4) vs ERNA (2)
Institutional Metric VTAK ERNA Criterion Row Edge
Market Capitalization
Scale
$548,639 $2.8M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+380.7% -94.1% Higher Growth VTAK
Operating Margin (TTM)
Profitability
-388.1% 0.0% Higher Margin ERNA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-111.3% -320.7% Higher ROE VTAK
52-Week Range Position
Momentum
1% ($0–$3) 10% ($0–$16) Stronger Trend ERNA
Beta / 30D Volatility
Risk Regime
0.19β · 76% Vol -5.48β · 90% Vol Lower Realized Risk VTAK
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 45.6 / 100 (HOLD) Higher Composite VTAK
Trailing 12M Revenue (USD)
Operating Scale
$1.9M $1,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.7% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$10M EBITDA ($4.87 Book/Sh · -111.3% ROE) -$12M EBITDA ($8.8M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VTAK +10.04 pp
VTAK: -24.76% · ERNA: -34.8%
3M Horizon ERNA +26.25 pp
VTAK: -80.29% · ERNA: -54.04%
6M Horizon ERNA +1460.07 pp
VTAK: -83.76% · ERNA: +1376.31%
1Y Horizon ERNA +181.17 pp
VTAK: -92.63% · ERNA: +88.54%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VTAK Revenue ERNA Revenue VTAK Op. Margin ERNA Op. Margin Margin Leader
FY2018 $10M $20M -498.0% 0.9% ERNA
FY2019 $10M $20M -801.9% -8.9% ERNA
FY2020 $0M $10M -13668.3% -125.0% ERNA
FY2021 $0M N/A -133027.3% N/A VTAK
FY2022 $0M N/A -192578.6% N/A VTAK
FY2023 $0M $0M -17674.0% -31080.9% VTAK
FY2024 $0M $0M -2676.9% -2693.1% VTAK
FY2025 $0M N/A -2581.6% N/A VTAK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ERNA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ERNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTAK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ERNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VTAK vs ERNA Key Questions & Quantitative Answers

As of Nov 16, 2026, Catheter Precision, Inc. (VTAK) is the stronger overall head-to-head candidate over Ernexa Therapeutics Inc. (ERNA) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). VTAK carries a Unified Composite Score of 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin), whereas ERNA carries 45.6/100 (HOLD) at $1.69 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile ERNA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VTAK leads the Growth & Scale pillar: VTAK posts +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin), compared with ERNA at -94.1% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (100.0% gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VTAK cumulative revenue shifted +0.0% while ERNA shifted -50.0%. In operating R&D and SG&A reinvestment, VTAK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ERNA.

VTAK screens cheaper on headline valuation multiples. VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin), whereas ERNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTAK (-111.3% ROE) versus ERNA (-320.7% ROE) capital efficiency.

In options market volatility and institutional positioning, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk). By comparison, ERNA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-5.48β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.